Clinical trials: PDAC - Pancreatic Ductal Adenocarcinoma
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- MiGIC (NCT07224750)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Diabetes, IPMN, Pancreatic
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g.
- Conditions
- Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- LASERBLOOD (NCT07659639)
- Testing
- Diagnostic procedures
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06122896
- Testing
- Screening Blood Tests, Endoscopic Ultrasound, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Patients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all.
- Trial name
- VAPOR (NCT05727020)
- Testing
- Breath test, Collection of matched samples of breath, biofluids and pancreatic tissue
- Where
- United Kingdom
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based…
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06151223
- Testing
- Bio-specimen Collection: Blood, Bio-specimen Collection: Pancreatic Juice, MRI
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages.
- Conditions
- Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- AI-LDCT-PC (NCT07117045)
- Testing
- Diagnostic Evaluation for Positive AI Findings
- Where
- 5 sites in China
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Pancreatic Cancer Stage I, Pancreatic Cancer Stage II
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control…
- Conditions
- Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- CLARITI (NCT06947382)
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 1,066 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.